Clinical treatment for retinoblastoma: report of 118 cases

Abstract

Objective To investigate the characteristics of clinical treatment and prognosis of 118 cases of retinoblastoma (RB). Methods A total of 118 RB children treated in our department from February 2008 to February 2018 were recruited in this study. All of them were evaluated by the International Classification for Intraocular Retinoblastoma (IIRC, A~E stage) and extraocular staging standard. Mainly according to their tumor stage, combined with their physical condition and the wishes of their parents, treatments such as intravenous chemotherapy, transpupillary thermotherapy (TTT), freezing and enucleation were applied. All cases were followed up for 1 to 10 years, and the clinical efficacy and prognosis of the patients were analyzed retrospectively. Results The 118 enrolled children (154 eyes) were 70 males and 48 females, at an average age of 25.94±20.88 months (1~122 months) at first visit, and 36 of them suffered from bilateral RB and 82 from single. Among them, 41 received chemotherapy, 57 chemotherapy combined with TTT, 10 chemotherapy combined with freezing, and 10 enucleation only. After treatment, 76 eyes (76/154) were salvaged, with a total salvage rate of 49.35%, and of them, 47 eyes were treated with chemotherapy combined with TTT, accounting for 61.84% (47/76). Seventy-eight eyes were enucleated, with a total extraction rate of 50.65% (78/154), and among 63 eyes at stage E, 53 were enucleated, accounting for 84.13%. During the mean follow-up time of 86.66±5.69 months, 22 (18.64%) children died, and 96 cases (81.36%) survived. The 5-year cumulative survival rate of single eye was 71.40%, and of bilateral was 80.00%. Conclusion Intravenous chemotherapy combined with TTT is one of the main ways for RB salvage. Enucleation is still the primary treatment for stage E eyes.

Keywords

• retinoblastoma
• chemotherapy
• survival rate
• transpupillary thermotherapy
• enucleation